Page 4,599«..1020..4,5984,5994,6004,601..4,6104,620..»

Monkey controls limb movements of 'avatar' using its mind

Posted: Published on February 23rd, 2014

Current ratings for: Monkey controls limb movements of 'avatar' using its mind Public / Patient: 5 1 rating Health Professionals: 0 0 ratings In the movie Avatar, humans operate the bodies of a human-hybrid species, called Na'vi, with their minds. Now, researchers from Harvard Medical School in Boston, MA, have carried out a similar technique in monkeys - using neural devices that allowed an alert monkey to control the mind of one that was temporarily paralyzed. The research team, including Ziv Williams of the Department of Neurosurgery at Harvard Medical School, says the findings provide proof of concept that such strategies could be used in the rehabilitation of patients who are paralyzed. The research was recently published in the journal Nature Communications. According to the investigators, previous research has demonstrated that neurons in many parts of the brain are able to control external devices, such as a cursor on a computer screen. This direct communication is known as brain-machine interface (BMI). The researchers say recent studies have even shown that using BMIs could potentially control robotic limbs. The rest is here: Monkey controls limb movements of 'avatar' using its mind … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Monkey controls limb movements of 'avatar' using its mind

Developmental gene influences sperm formation, fruit fly model demonstrates

Posted: Published on February 23rd, 2014

Heidelberg researchers have been delving into the basic regulatory mechanisms of stem cell differentiation. Using the Drosophila melanogaster fruit fly as a model organism, the team led by Prof. Dr. Ingrid Lohmann at Heidelberg University's Centre for Organismal Studies was able to show how a special developmental gene from the Hox family influences germline stem cells. These cells are responsible for sperm formation. The scientists, working in the Maintenance and Differentiation of Stem Cells in Development and Disease Collaborative Research Centre (CRC 873), found that impairment of Hox gene function resulted in prematurely aged sperms. As immature somatic cells, stem cells can mature into different types of cells, thus making them responsible for the development of all the tissues and organs in the body. They are also able to repair damaged adult cells. Advancements in medical research have shown that stem cells can be used to treat certain diseases. To fulfil the promise of stem cell therapy, it is important to discover the function of the respective stem cells and understand how they interact with their environment, that is, the surrounding cells and tissues, explains Prof. Lohmann, who heads the Developmental Biology research group at the Centre for Organismal Studies … Continue reading →

Posted in Stem Cell Research | Comments Off on Developmental gene influences sperm formation, fruit fly model demonstrates

STAP stem cell doubts keep proliferating

Posted: Published on February 23rd, 2014

Doubts keep growing about the stunning discovery that super stem cells could be created merely by placing white blood cells from young mice in acid or otherwise stressing them, says Paul Knoepfler, a stem cell researcher at UC Davis. Among other inconsistencies, Knoepfler referred to several unexplained anomalies in images of these STAP cells in two papers, published by the prestigious journal Nature on Jan. 29. One image appears to suggest signs that virtually all cells treated with an acid bath were being reprogrammed, a result that would be extraordinary. Stem cell reprogramming to date has been inefficient, with a low percentage of treated cells being reprogrammed. "The more I look at these two STAP papers, the more concerned I get ... The bottom line for me now is that some level a part of me still clings to a tiny and receding hope this has all been overblown due to simple misunderstandings, but that seems increasingly unlikely," Knoepfler wrote Sunday on his blog, IPS Cell. This undated image made available by the journal Nature shows a mouse embryo formed with specially-treated cells from a newborn mouse that had been transformed into stem cells. Researchers in Boston and Japan say … Continue reading →

Comments Off on STAP stem cell doubts keep proliferating

Immune cells regulate blood stem cells, research shows

Posted: Published on February 23rd, 2014

Researchers in Bern have discovered that, during a viral infection, immune cells control the blood stem cells in the bone marrow and therefore also the body's own defenses. The findings could allow for new forms of therapy, such as for bone marrow diseases like leukemia. During a viral infection, the body needs various defense mechanisms -- amongst other things, a large number of white blood cells (leukocytes) must be produced in the bone marrow within a short period of time. In the bone marrow, stem cells are responsible for this task: the blood stem cells. In addition to white blood cells, blood stem cells also produce red blood cells and platelets. The blood stem cells are located in specialized niches in the bone marrow and are surrounded by specialized niche cells. During an infection, the blood stem cells must complete two tasks: they must first recognise that more blood cells have to be produced and, secondly, they must recognise what kind of. Now, for the first time, researchers at the Department of Medical Oncology at the University of Bern and Bern University Hospital headed by Prof. Adrian Ochsenbein have investigated how the blood stem cells in the bone marrow are … Continue reading →

Comments Off on Immune cells regulate blood stem cells, research shows

Telephone Activity Report: Picomedicine | Femto Medicine …

Posted: Published on February 23rd, 2014

General Information Geographic Whois Reference Type of Code: General Purpose Code Is this code assignable: Yes If not, why: Geographic(G) or non-geographic(N): G If non-geographic, usage: Is this code reserved for future use: No Is this code assigned: Yes Is this code in use: Y In service date: 06/13/1998 Activities on Domain: femtomedicine.com Domain Create Time: 2/12/2010 12:00:00 AM Domain Update Time: 5/30/2013 12:00:00 AM Domain Expired Time: 2/12/2023 12:00:00 AM Domain Whois Server: whois.meshdigital.com domain name: femtomedicine.com registrar: mesh digital limited whois server: whois.meshdigital.com name server: ns1.managementserver.net name server: ns2.managementserver.net status: clientdeleteprohibited status: clienttransferprohibited status: clientupdateprohibited updated date: 30-may-2013 creation date: 12-feb-2010 expiration date: 12-feb-2023 notice: the expiration date displayed in this record is the date the registrar's sponsorship of the domain name registration in the registry is currently set to expire. this date does not necessarily reflect the expiration date of the domain name registrant's agreement with the sponsoring registrar. users may consult the sponsoring registrar's whois database to view the registrar's reported date of expiration for this registration. terms of use: you are not authorized to access or query our whois database through the use of electronic processes that are high-volume and automated except as reasonably necessary … Continue reading →

Posted in Picomedicine | Comments Off on Telephone Activity Report: Picomedicine | Femto Medicine …

Stem cells to fight brain diseases say Cambridge scientists

Posted: Published on February 23rd, 2014

Cambridge News Follow us on Sunday 23 Feb 2014 7:49 PM Written byELEANOR DICKINSON Sufferers of serious brain diseases could one day be helped by stem cell treatments , according to scientists at Cambridge University. Scientists at the University hope to be able to use the regenerative power of stem cells to treat major brain conditions such as Parkinsons and Huntingtons disease. Their findings are expected to be revealed at the Cambridge Festival of Science next month. Robin Franklin, the newly appointed Professor of Stem Cell Medicine, will be discussing his research into central nervous system regeneration and the possibility of treating multiple sclerosis. He said: The brain, although capable of unmatched feats of adaptability, is generally considered to be an organ that is very poor at mending itself after injury. However, one particular type of brain cell, called the oligodendrocyte the cell that makes the myelin wrapping around nerve fibres can be regenerated when lost in disease by the brains own stem cells. By studying in the laboratory how brain stem cells generate new oligodendrocytes it has been possible to identify ways in which this important regenerative process might be achieved in the clinic, offering the Read the original … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Stem cells to fight brain diseases say Cambridge scientists

Okyanos Heart Institute CEO Matt Feshbach to Speak on Panel at International Stem Cell Society Global Conference

Posted: Published on February 23rd, 2014

Freeport, The Bahamas (PRWEB) February 21, 2014 Okyanos Heart Institute, whose mission it is to bring a new standard of care and a better quality of life to patients with coronary artery disease using adult stem cell therapy, announces CEO Matt Feshbach will present at the STEMSO Conference. He will join a panel to discuss the opportunities available through the new stem cell research and Therapy Act. The conference will be held at the Grand Lucayan Resort in Freeport, Grand Bahamas, February 19-22, 2014. The panel discussion will be Friday, February 21 from 8:45 9:45 a.m. The conference, titled Bridging the Gap: Research to Point of Care, brings together medical scientists, clinicians, regulatory experts, and investors to discuss progress in the field of research and clinical protocols and the process of taking promising therapies to fight chronic disease to market in a responsible manner. Friday opening remarks will be delivered by Ian Rolle, President of Grand Bahama Port Authority from 8:30 a.m. to 8:45 a.m. followed by the panel presentation until 9:45 a.m. which, in addition to Rolle will include Feshbach, Mitchell Fuerst, Esq., managing partner, Fuerst, Ittleman, David and Joseph. The panel will be moderated by Arthur K. Parris, … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Okyanos Heart Institute CEO Matt Feshbach to Speak on Panel at International Stem Cell Society Global Conference

Katie's family 'holding our breath' – stem cell donor clinic Saturday

Posted: Published on February 23rd, 2014

Cambridge Times CAMBRIDGE The family of four-year-old Katie Herron is anxiously waiting to find out if chemotherapy was successful enough to put her into remission and give her a chance at the stem cell transplant that could save her life. The Cambridge girl, who is facing cancer for the second time, is in Toronto Sick Kids hospital fighting for her life after normally successful treatments didnt beat her childhood leukemia. Herrons only hope is to receive a stem cell transplant, but she desperately needs to find a donor match first. Its hoped that chances of finding a potential donor will increase thanks to a stem cell donor clinic scheduled for Saturday (Feb. 22). The clinic will run from 1 to 5 p.m. at Cambridge Sports Park, located at the corner of Franklin Boulevard and Can-Amera Parkway. The Herron family is encouraging residents to come to the clinic and register as a donor with OneMatch, which co-ordinates the worldwide registry. Registering as a donor is a simple as a swab of the cheek. However, even if a match is found, the four-year-olds fatigued body still needs to get healthy enough to have the procedure. Herron continues to undergo a battery of … Continue reading →

Posted in Stem Cell Transplant | Comments Off on Katie's family 'holding our breath' – stem cell donor clinic Saturday

California Stem Cell Announces U.S. FDA Approval of Phase …

Posted: Published on February 23rd, 2014

IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Companys application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer. The randomized, double-blind study is the Companys second cancer therapy approved for clinical trials by the FDA, bolstering its platform approach to treating late stage solid-tumor cancers. The Companys patient-specific approach to treating metastatic melanoma, recently approved to begin a Phase III trial, provided sufficient safety data to proceed directly to a Phase II study in ovarian cancer. Led by Chief Medical Officer Robert Dillman, M.D., the study design randomizes an estimated 99 adult female patients to two treatment arms. The treatment group will receive Ovapuldencel-T, which is a combination of autologous dendritic cells loaded with irradiated autologous tumor cells in GM-CSF. Ovapuldencel-T is created by first isolating cancer stem cells from the patient's resected tumor sample, then enriching, inactivating and combining these cells with dendritic cells or antigen-presenting immune cells which are harvested from the patients blood. The control group will receive the MC treatment, harvested from the … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on California Stem Cell Announces U.S. FDA Approval of Phase …

California Stem Cell announces FDA approval of Phase II …

Posted: Published on February 23rd, 2014

Published 18 February 2014 California Stem Cell has announced that the US Food and Drug Administration (FDA) has approved the companys application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer. The randomized, double-blind study is the company's second cancer therapy approved for clinical trials by the FDA, bolstering its platform approach to treating late stage solid-tumor cancers. The company's patient-specific approach to treating metastatic melanoma, recently approved to begin a Phase III trial, provided sufficient safety data to proceed directly to a Phase II study in ovarian cancer. Led by chief medical officer Dr Robert Dillman, the study design randomizes an estimated 99 adult female patients to two treatment arms. The treatment group will receive Ovapuldencel-T, which is a combination of autologous dendritic cells loaded with irradiated autologous tumor cells in GM-CSF. Ovapuldencel-T is created by first isolating cancer stem cells from the patient's resected tumor sample, then enriching, inactivating and combining these cells with dendritic cells - or antigen-presenting immune cells - which are harvested from the patient's blood. The control group will receive the 'MC' treatment, harvested … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on California Stem Cell announces FDA approval of Phase II …

Page 4,599«..1020..4,5984,5994,6004,601..4,6104,620..»